Simplex Trading
AVBP icon

Simplex Trading’s ArriVent BioPharma AVBP Stock Holding History

Simplex Trading’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
50,000
+49,400
+8,233% +$1.12M ﹤0.01% 2347
2025
Q4 		$12.1K Sell
600
-20,600
-97% -$429K ﹤0.01% 6867
2025
Q3 		$391K Buy
+21,200
New +$417K ﹤0.01% 4140

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Simplex Trading's AVBP Position: Q1 2026 in Review

Simplex Trading sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 45,558 shares — an estimated $1.03M sold.

Simplex Trading first reported a position in AVBP in Q2 2025 and held it in 3 quarters. The position peaked at $917K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Simplex Trading reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 45,558 ArriVent BioPharma shares in Q1 2026, an estimated $1.03M.
  • Simplex Trading first reported a position in ArriVent BioPharma in Q2 2025 and held it in 3 quarters.
  • Simplex Trading's ArriVent BioPharma position peaked at $917K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.